Phase II study of everolimus for recurrent or progressive pediatric ependymoma is a research paper published in Neuro-Oncology Advances (2023). On theSindex it has a DataRank of 0.344. It has been cited 5 times, with 5 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0.0750
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
National Institutes of Health
Grant: 1UL1TR003163-01A1
National Institutes of Health
Grant: 1KL2TR003981-01A1]
National Institutes of Health
Grant: P30 CA008748]
NCI NIH HHS
Grant: P30 CA008748
Children’s Health System of Texas
Novartis Pharmaceuticals Corporation
Memorial Sloan Kettering Cancer Center
Making Headway Foundation
Keywords